Charles River utilizes a truly integrated approach to small molecule drug discovery, uniting all of the key disciplines required to achieve a program's goals in a single project team. As an experienced drug discovery organization, we are able to tailor project resources to meet the client's specific needs, integrating chemistry, physical sciences, CADD, biology, structural biology, ADMET/PK and disease models as required.

Acquisition of Argenta & BioFocus

This acquisition positions us as an early-stage CRO with in vitro and in vivo capabilities from target identification and validation through preclinical development. Learn more »

I need to...